Form 144 AtriCure, Inc. Filed by: Noznesky Justin J
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
AtriCure Inc. (ATRC) PT Lowered to $58 at BTIG
May 2, 2024 5:25 AM EDTBTIG analyst Marie Thibault lowered the price target on AtriCure Inc. (NASDAQ: ATRC) to $58.00 (from $65.00) while maintaining a Buy rating.
The analyst comments "AtriCure reported Q1 revenue of $108.9M (+16.4% y/y rep, +16.3% y/y cc), above consensus of $106.9M. U.S. Q1 revenue was $90.2M (+15.4% y/y), slightly higher than consensus of $89.5M, and International revenue of $18.6M (+21.5% y/y rep, +21.1% y/y cc) beat consensus of $17.4M. The closely watched U.S. Appendage Management segment reported $35.9M (+11% y/y) in Q1 sales, missing consensus... More
